Your browser doesn't support javascript.
loading
Five cases of seronegative persistent inflammatory monoarthritis improved with biological therapy.
Izumiyama, Takuya; Mori, Yu; Hamada, Soshi; Kurishima, Hiroaki; Mori, Naoko; Aizawa, Toshimi.
Afiliação
  • Izumiyama T; Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
  • Mori Y; Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
  • Hamada S; Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
  • Kurishima H; Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
  • Mori N; Department of Diagnostic Radiology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
  • Aizawa T; Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Mod Rheumatol Case Rep ; 7(1): 307-314, 2023 01 03.
Article em En | MEDLINE | ID: mdl-35959594
ABSTRACT
Persistent inflammatory monoarthritis is defined as inflammation of one joint that continues for longer than 3 months. Most cases remain as nonspecific arthritis after several years. Persistent inflammatory monoarthritis is difficult to diagnose and treat in the early stage because there are no criteria for diagnosis and treatment. We report five seronegative persistent inflammatory monoarthritis cases that affected the left knee, right knee, left knee, left ankle, and right knee. All patients underwent joint punctures; two patients received steroid injections in the affected joint. The bacterial and mycobacterial culture were negative in all patients. Two patients received oral steroids, and two patients were administered nonsteroidal anti-inflammatory drugs; however, their symptoms did not improve, and one patient experienced progression of joint destruction. We investigated the usefulness of biological disease-modifying antirheumatic drugs for the treatment of seronegative persistent inflammatory monoarthritis. We obtained a remarkable improvement effect and prevented the advance of joint destruction.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite / Antirreumáticos Limite: Humans Idioma: En Revista: Mod Rheumatol Case Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite / Antirreumáticos Limite: Humans Idioma: En Revista: Mod Rheumatol Case Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão